Novavax posts higher-than-expected revenue, says prepared to further cut costs
A vial labelled “Novavax V COVID-19 Vaccine” is seen in this illustration taken January 16, 2022. REUTERS/Dado Ruvic/Illustration Acquire Licensing Rights Nov 9 (Reuters) – COVID-19 vaccine maker Novavax (NVAX.O) … Read More
